Financial Data and Key Metrics Changes - The company achieved high single-digit reported revenue growth and low double-digit adjusted EPS growth in Q4, with sales growing 7% on a reported basis and 6% in constant currency [6][8] - Adjusted EPS grew low double digits to $4.53, while GAAP EPS was $3.77 [8][31] - For the full year, sales grew 7% on both a reported and constant currency basis, with adjusted EPS growing 11% to $13.13 [9][31] Business Line Data and Key Metrics Changes - Recurring revenue grew 9%, driven by chemistry growth, while instruments grew 3%, led by high single-digit LCMS growth [8][30] - Chemistry revenue grew 12% for the full year, contributing to the overall growth [9][31] - Instrument sales grew 5% for the full year, with high single-digit LCMS growth offset by a low single-digit decline in TA system sales [31][32] Market Data and Key Metrics Changes - Pharma revenue grew 9%, with high single-digit growth across Americas and Europe and low double-digit growth in Asia [13][31] - Industrial grew 6%, while academic and government declined 1% [31] - In China, sales grew 9% for the year, driven by strong performance in biotech and CDMOs [14][32] Company Strategy and Development Direction - The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, aiming to strengthen its position in high-growth adjacencies and enhance operational execution [6][17] - The strategic roadmap laid out five years ago continues to advance, with a focus on innovation and high-volume testing opportunities [7][9] - The company plans to expand its idiosyncratic growth driver framework from three to five drivers, adding biologics and informatics [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong growth in 2026, with a guidance range of 5.5%-7% for organic constant currency revenue growth [35][36] - The company anticipates approximately $3 billion in revenue contribution from the acquired business in 2026, with a risk-adjusted growth assumption of 2.5% [26][35] - Management highlighted the importance of improving operational execution and pricing discipline to enhance revenue synergies [47][57] Other Important Information - The company expects to realize approximately $55 million of adjusted EBIT from cost synergies in 2026 and $50 million in revenue synergies [23][36] - Free cash flow totaled $677 million for the full year, with a net debt position of $820 million at year-end [34][36] Q&A Session All Questions and Answers Question: Concerns about BD results and recovery path - Management acknowledged several issues that emerged in Q4 impacting growth, emphasizing a focus on improving operational execution and leveraging new product launches for recovery [44][46] Question: Full year guidance and deceleration - Management clarified that the guidance reflects a prudent approach, incorporating potential headwinds and assuming mid-single-digit growth in China [54][55] Question: Synergy targets and operational excellence - Management confirmed a focus on achieving synergy targets through operational improvements and disciplined pricing strategies [66][70]

Financial Data and Key Metrics Changes - The company achieved high single-digit reported revenue growth and low double-digit adjusted EPS growth in the fourth quarter, with sales growing 7% on a reported basis and 6% in constant currency [6][9] - Adjusted EPS grew 10% to $4.53, while GAAP EPS was $3.77 [33][34] - For the full year, sales grew 7% on both a reported and constant currency basis, with adjusted EPS growing 11% to $13.13 [10][34] Business Line Data and Key Metrics Changes - Recurring revenue grew 9%, driven by chemistry growth, while instrument revenue grew 5%, led by high single-digit LCMS growth [9][10] - Chemistry revenue grew 12% for the full year, significantly above the historical average growth rate of 7% [12][34] - The transition to a subscription-based model for Empower reduced overall instrument growth by a low single-digit percentage for the quarter, but is expected to provide long-term recurring revenue benefits [9][10] Market Data and Key Metrics Changes - Pharma revenue grew 9%, with high single-digit growth across the Americas and Europe, and low double-digit growth in Asia [15][31] - Industrial revenue grew 6%, while academic and government declined 1% [33] - In China, the company grew 9% for the year, driven by strong performance in biotech and CDMOs [16][34] Company Strategy and Development Direction - The company completed the acquisition of BD's Biosciences and Diagnostic Solutions business, aiming to strengthen its position in high-growth adjacencies and enhance operational execution [6][19] - The strategic roadmap laid out five years ago continues to advance, with a focus on innovation and commercial execution [8][10] - The company plans to expand its idiosyncratic growth driver framework from three to five drivers, adding biologics and informatics to the existing drivers [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong growth in 2026, with a blended year-over-year revenue growth of approximately 5.3% at the midpoint of the combined company [29][38] - The company expects to realize approximately $50 million in revenue synergies in 2026, reflecting initial contributions from commercial excellence initiatives [38][39] - Management highlighted the importance of improving operational execution and pricing discipline to enhance revenue and profitability [48][58] Other Important Information - The company expects to achieve approximately $55 million of adjusted EBIT from cost synergies in 2026 [25][39] - Free cash flow totaled $677 million for the full year, with a net debt position of $820 million at the end of the year [36][39] Q&A Session Summary Question: Insights on BD results and path to recovery - Management acknowledged several issues that emerged in Q4 impacting growth, but emphasized that these will now be present in a lower baseline for 2026, allowing for potential upside [45][47] Question: Impact of Empower transition on instruments - Management noted that the transition to subscription has created a low single-digit headwind to overall instrument numbers, but expressed confidence in the strong performance of LCMS and the overall instrument funnel [46][52] Question: Full year guidance and deceleration - Management explained that the guidance reflects prudence and incorporates assumptions about various market segments, including academic and government, and the impact of the Empower transition [55][56] Question: Update on pro forma leverage and interest expense - Management indicated that net debt is expected to be around 2.4x net debt to EBITDA, with plans to reduce it below 2 times within 18 months [63][64] Question: Synergy targets and operational execution - Management confirmed that they are on track to deliver the commitments made during the deal announcement, with a focus on identifying opportunities for cost synergies [67][70]

J.P. Morgan 44th Annual Healthcare Conference Udit Batra, Ph.D. President & CEO January 12, 2026 Forward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements: This presentation includes "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed transaction among Waters Corporation ("Waters" or the "Com ...

Summary of InMode Conference Call Company Overview - **Company**: InMode - **Founded**: 17 years ago by Moshe Mizrahy - **Headquarters**: Israel - **Employees**: 650 worldwide, plus 200 in manufacturing - **Revenue Growth**: From $22 million in 2017 to $500 million in 2023, indicating rapid growth [7][20] Core Business and Technology - **Focus**: Aesthetic and wellness medical treatments, utilizing minimally invasive technology rather than traditional optical energy methods [6][8] - **Key Products**: - BodyTite platforms for fat melting and skin tightening - Empower for women's health, targeting vaginal laxity and urinary incontinence - InVision for dry eye treatment [7][12][13] Market Dynamics - **Current Market Challenges**: - Revenue decline of 20% expected in 2024 due to high inflation (8%-9%) and increased interest rates (13%-14%) affecting equipment financing for doctors [19][20] - Projected revenue for 2023 is approximately $370 million [20][21] - **Gross Margin**: Maintained at 80% despite market challenges, with EBITDA above 20% [20] Future Growth Opportunities - **Women's Health**: - Ongoing FDA studies for urinary incontinence and overactive bladder, expected to complete by end of 2026 [11][14] - Empower product generated $40 million in its first year [12] - **Ophthalmology**: - InVision product for dry eye treatment sold $30 million in its first year, with expectations to exceed $50 million annually in the future [13] - **International Expansion**: - Established subsidiaries in Japan, Argentina, and Thailand, aiming to increase direct sales from 80% to 85% [22][24] - Potential growth in China, with plans to expand product offerings as additional clearances are obtained [24][38] Sales and Marketing Strategy - **Sales Force**: - Approximately 300 direct salespeople globally, with 210 in the U.S. [30] - Leadership changes made to streamline management and improve sales momentum [31][32] - **Marketing Investments**: Increased spending on marketing to support direct sales efforts [22] Financial Strategy - **Capital Allocation**: - $508 million spent on stock buybacks, with a shift in focus towards exploring M&A opportunities [33][34] - No current M&A pipeline, but interest in acquiring companies related to women's health and wellness [34] Product Development - **Upcoming Products**: - Development of four laser types (CO2, Erbium, Q-Switch, PICO) to complement existing RF technology, expected to launch between 2026 and 2027 [35][36] Conclusion - InMode is navigating a challenging market environment but remains optimistic about future growth through product innovation, international expansion, and strategic management of its sales force and financial resources [20][21][22]

Summary of Conference Call Company and Industry - **Company**: Waters Corporation - **Industry**: Life Sciences and Analytical Instruments Key Points and Arguments Replacement Cycle and Growth Drivers - The replacement cycle for instruments, particularly LCMS, began about a year ago and is expected to continue for several more years, with current growth rates in the high single digits [2][4] - The growth drivers for LCMS include: 1. Instrument replacement cycle, which is still ongoing [2] 2. Idiosyncratic growth drivers such as GLP-1 testing, which has seen revenues double, and PFAS testing, which has 30% order growth [3] 3. Development of new products that meet significant unmet needs in the market [3] Performance in Different Segments - Chemistry segment grew by 13% in the third quarter, significantly above the pre-COVID run rate of 6%-7% [5] - The growth in chemistry is attributed to investments in bioseparations and innovations in product offerings, particularly for biologics [6][7] - The pharma segment experienced double-digit growth driven by the replacement cycle and idiosyncratic growth drivers, particularly in the U.S. and Europe [10][11] Regional Insights - In China, growth is driven by CDMOs supporting the local biotech industry, with a significant share of global in-licensing coming from China [11] - India is experiencing high teens growth driven by generics, while branded generics in China are still declining [11] Innovation and New Products - The CDMS opportunity is highlighted as a significant unmet need in the market, with potential to capture a large share of the $350 million annual sales currently dominated by existing techniques [16][17] - New product launches include the FACS DiVa S8 flow cytometer and the FXI incubator for microbiology, both expected to drive significant growth [22][23] Software and Commercial Model Changes - The Empower software business is a critical part of Waters' portfolio, with plans to transition to a subscription model to enhance revenue [30][31] - The Empower system is used for 80% of QAQC data submissions for drugs filed to regulatory bodies, indicating its importance in the industry [30] Market Dynamics and Future Outlook - The overall market setup is positive, with continued growth expected from the replacement cycle, new product introductions, and idiosyncratic growth drivers [38] - The company anticipates that the growth rate in chemistry will stabilize in the high single digits to low double digits over time [7] Additional Insights - The company is focusing on integration planning post-acquisition, with positive surprises in microbiology workflow improvements and potential market entry strategies [26] - The pricing strategy for large molecules is expected to be stickier and more significant compared to small molecules, enhancing revenue opportunities [9] Other Important Content - The company is actively working on enhancing its product offerings and market strategies to capture unmet needs and drive sustainable growth [17][38] - There is a focus on customer adoption and integration of new technologies, which is crucial for maintaining competitive advantage in the market [17][31]

Financial Data and Key Metrics Changes - The company reported sales of $800 million for the third quarter, reflecting an 8% increase both as reported and in constant currency [23][26] - Non-GAAP earnings per share increased by 16% to $3.40, exceeding the midpoint of guidance by $0.20 [8][25] - Gross margin for the quarter was 59%, a 70 basis point increase from the previous quarter [26] Business Line Data and Key Metrics Changes - Instrument sales grew by 6%, driven by high single-digit growth in the LC-MS portfolio [25] - Recurring revenue increased by 9%, with service revenue up 7% and Chemistry revenue up 13% [25][26] - Chemistry products saw a significant boost, with new product launches contributing to a 13% growth in the segment [12][25] Market Data and Key Metrics Changes - By end market, Pharma grew 11%, Industrial grew 4%, and Academic and Government grew 1% [23][25] - Asia experienced a 13% growth, while Europe and the Americas each grew by 5% [25] - In China, sales grew by 12%, driven by double-digit growth in Pharma and Academic & Government sectors [25] Company Strategy and Development Direction - The company is focused on innovation and expansion into high-growth areas, including bioanalytical characterization and bioseparations [7][11] - The pending combination with BD's Bioscience & Diagnostic Solutions business is expected to create significant value and synergies [21][22] - The company plans to launch a series of new products in 2026, enhancing its competitive position in the market [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing instrument replacement cycle and the potential for sustained growth driven by innovation [30][77] - The external environment is improving, with more stable global trade conditions and a clearer policy backdrop for Pharma customers [27][30] - The company raised its full-year 2025 guidance, expecting constant currency sales growth in the range of 6.7%-7.3% [15][28] Other Important Information - The company is seeing strong demand for GLP-1 testing and PFAS testing, which are key growth drivers [9][10] - The integration planning for the BD transaction is progressing rapidly, with a focus on achieving synergies [21][22] Q&A Session Summary Question: Can you provide more color on Pharma strength in the Americas and China? - Management noted double-digit growth in Pharma across all regions, driven by the success of the replacement cycle and new product traction [35][36] Question: What are your thoughts on the BD transaction and revenue synergies? - Management expressed confidence in achieving revenue synergies and highlighted the integration planning efforts underway [44][49] Question: Can you clarify on the fourth quarter guidance and any pull-forwards? - Management indicated no pull-forwards were observed, with orders growing more than sales, leading to a healthy backlog [56][57] Question: How do you see the biosimilar opportunity evolving? - Management is optimistic about the shift towards analytical testing for biosimilars, which aligns with the company's strategy [50][51]

Q3 2025 Performance Highlights - Waters Corporation reported Q3 2025 revenue of $800 million, with constant currency (CC) revenue growth of 8%[10] - CC recurring revenue growth was 9%[10] - CC instrument growth was 6%[10] - Q3 2025 Non-GAAP EPS grew by 16% to $3.40[10] - High single-digit (HSD) LC-MS growth and 17% CC growth were achieved[10] Growth Drivers and Innovation - BioAnalytical Characterization new products saw an 11% sequential growth in instrument sales from Q2 2025 to Q3 2025[13, 14] - Chemistry growth was 11% year-to-date in constant currency, driven by new BioSeparations products[16, 17] - Waters Alliance iS sales grew +300% in constant currency in 3Q25 compared to 3Q24[14] - Waters Xevo TQ Absolute sales grew +30% in constant currency in 3Q25 compared to 3Q24[14] Geographic and Market Performance - Pharma sales growth in Q3 2025 in constant currency was 11% overall, with strong performance across Americas, Europe, and Asia ex-China[19, 20] - Asia experienced 13% growth, Americas and Europe both saw 5% growth[34, 35] Guidance - The company projects FY 2025 constant currency revenue growth between 6.5% and 7.1%[37] - The company projects Q4 2025 constant currency revenue growth between 5.2% and 7.2%[37] - Non-GAAP EPS for FY 2025 is projected to be between $13.05 and $13.15[37] - Non-GAAP EPS for Q4 2025 is projected to be between $4.45 and $4.55[37]

Core Insights - Technology is enhancing financial management by providing tools that automate finances, measure progress, and offer insights into improvement areas [1] Group 1: Budgeting Apps - YNAB (You Need a Budget) is highlighted as a top budgeting app for 2025, utilizing a zero-based budgeting approach that assigns every dollar a specific purpose [2][3] - Users of YNAB save an average of $6,000 per year, making the annual fee of $109 potentially worthwhile for those committed to budgeting [5] - Empower is another budgeting tool that offers a comprehensive view of finances by aggregating information from various accounts to calculate net worth in real-time, although it may not be as strong in budgeting as YNAB [6]

Core Insights - Natera has achieved significant growth since its IPO, with stock prices increasing nearly 10 times from $18 to around $170 and revenues expanding from $190 million to $2 billion, reflecting a 44% revenue growth over the last twelve months [3][11]. Company Overview - Natera specializes in molecular diagnostics, particularly in cancer detection and monitoring, positioning itself as a leader in medical intelligence [4]. - The company's flagship product, Signatera, is a personalized tumor-informed test that utilizes a simple blood draw to detect circulating tumor DNA, revolutionizing cancer monitoring [5][6]. Product and Technology - Natera's technology allows for non-invasive liquid biopsies, providing doctors with critical insights into cancer progression and recurrence risk [6]. - In addition to Signatera, Natera offers Altera for genomic profiling and Empower for hereditary cancer screening, creating a comprehensive suite for cancer care [6]. Market Potential - In the latest quarter, Natera processed over 850,000 tests, generating $546.6 million in revenue, with oncology-related tests growing at 50% year-over-year [9]. - The cell-free DNA testing market is projected to nearly double from $11 billion to around $20 billion in five years, indicating substantial growth potential for Natera [12]. Financial Projections - Natera is expected to sustain 25% annual revenue growth over the next few years, potentially increasing revenue from $1.7 billion last year to approximately $7 billion by 2030 [11]. - If Natera achieves $7 billion in revenue while maintaining a price-to-sales multiple of 13x, the stock price could reach about $700, even with potential multiple compressions [13]. Growth Opportunities - Key areas for growth include expanding the oncology market, scaling internationally, entering adjacent markets, and increasing volume and penetration within existing markets [17]. - Broader insurance coverage and clinical evidence supporting test adoption are critical for expanding market size and pricing power [18]. Competitive Landscape - Natera competes with major players like Roche, Danaher, and Abbott, which have significantly higher revenues, indicating that Natera is still in the early stages of its growth story [12]. - The company must navigate challenges such as reimbursement issues, competitive pressure, regulatory hurdles, and the pace of international adoption [18].

Core Insights - The article emphasizes the importance of growing net worth in one's 50s, as individuals are typically nearing retirement and may be in their highest-earning years [1] Financial Habits to Grow Net Worth - Maxing out retirement contributions is crucial, with catch-up contributions allowed for those over 50, enabling contributions of $8,000 to IRAs and $31,000 to 401(k) or 403(b) plans [5] - Eliminating high-interest debt is recommended to protect retirement funds, with suggestions for refinancing or consolidating debts to lower overall interest [6] - Regularly tracking net worth is advised, with quarterly reviews using tools like Empower to monitor progress and adjust savings or spending habits as needed [9] Average Net Worth by Age - The average net worth increases significantly with age, with figures such as $1,285,558 for individuals in their 50s and $1,512,799 for those in their 60s, indicating a trend of growing wealth as individuals approach retirement [7]